CAS: 1299440-37-1 - Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
Formula:Unspecified
- Synonyms:
- Uplizna
- Inebilizumab-cdon
- Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
- Inebilizumab
- MEDI 551
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Inebilizumab REF: TM-T76713CAS: 1299440-37-1 | SDS-PAGE:99.3%;SEC-HPLC:96.2% | 153.00 €~2,135.00 € | Tue 03 Dec 24 |
 | Inebilizumab REF: 3D-CLA1393CAS: 1299440-37-1 | - - - | To inquire | Fri 13 Dec 24 |
Inebilizumab
CAS:1299440-37-1
Inebilizumab: humanized anti-CD19 antibody, enhances cytotoxicity against B cells, treats autoimmune diseases like MS.
Purity:
SDS-PAGE:99.3%;SEC-HPLC:96.2%
Color and Shape:
Liquid
Molecular weight:
146.60 kDa
Ref: TM-T76713
| 1mg | 153.00 € | ||
| 5mg | 373.00 € | ||
| 10mg | 618.00 € | ||
| 25mg | 926.00 € | ||
| 50mg | 1,276.00 € |
Estimated delivery in United States, on Tuesday 3 Dec 2024
Inebilizumab
CAS:1299440-37-1
Anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cell.
Ref: 3D-CLA1393
| Undefined size | To inquire |
Estimated delivery in United States, on Friday 13 Dec 2024
